Amends TCA Title 53 and Title 63.

Tennessee HB0192 enacts the "Individualized Investigational Treatment Act," allowing manufacturers and eligible facilities to provide individualized investigational treatments based on a patient's genetic profile to patients with life-threatening or severely debilitating illnesses. The bill outlines the criteria for eligible patients and the informed consent process, clarifies that it does not mandate insurance coverage for such treatments, and protects healthcare providers from disciplinary actions related to recommending these treatments. Additionally, it prohibits state officials from obstructing patient access to these treatments and ensures that patients' heirs are not liable for debts incurred from the treatment if the patient dies.